自体干细胞移植联合 CAR-T 细胞治疗难治/复发 B 细胞淋巴瘤：单臂临床研究

Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cells (CAR-T) have been used as consolidation therapies for patients with refractory/relapsed B cell non-Hodgkin's lymphoma (R/R B-NHL) in remission after second-line chemotherapy or salvage therapy.

However, patients with different pathological subtypes and remission states may benefit differently from ASCT or CAR-T cell therapy.

Furthermore, consolidation treatment involving ASCT or CAR-T cells still poses a significant risk of disease relapse.

We conducted a retrospective, single-arm study of 47 patients with R/R B-NHL, and found that the combination of ASCT and CAR-T therapy improved the 3-year progression-free survival (PFS) and overall survival (OS) rates to 66. 04% (95%CI: 48. 311-78. 928) and 72. 442% (95%CI: 53. 46-84. 708) respectively.

Furthermore, the combination therapy has no serious adverse events.

Thus, ASCT combined with CAR-T cell therapy is effective against multiple subtypes of R/R B-NHL, and can effectively prolong the long-term survival of patients.